COVID-19 Clusters in Belgian Nursing Homes: Impact of Facility Characteristics and Vaccination on Cluster Occurrence, Duration and Severity.

SARS-CoV-2 clusters infection prevention long-term care facilities vaccination

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
13 01 2023
Historique:
received: 29 11 2022
revised: 06 01 2023
accepted: 09 01 2023
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

COVID-19 severely affected nursing home residents from March 2020 onwards in Belgium. This study aimed to model the impact of vaccination and facility characteristics on cluster occurrence, duration and severity in this setting. Possible clusters were identified between June 2020 and January 2022, based on the Belgian COVID-19 surveillance in nursing homes. Median attack rates (AR) among residents and staff, case hospitalization rates (CHR) and case fatality rates (CFR) were calculated. A negative binomial model was used to identify the association between nursing home characteristics and the number of cases, hospital admissions and deaths and the duration of the cluster. A total of 2239 clusters were detected in more than 80% of nursing homes. Most of these (62%) occurred before the start of COVID-19 vaccination (end of December 2020). After vaccination, the number of clusters, the AR among residents and staff, the CHR and the CFR dropped. Previous cluster(s) and vaccination decreased the number of cases, hospital admissions and deaths among residents. Previous cluster experience and having started vaccination were protective factors. We recommend continued implementation of targeted interventions such as vaccination, large-scale screening and immediate implementation of additional infection prevention and control measures.

Identifiants

pubmed: 36680272
pii: v15010232
doi: 10.3390/v15010232
pmc: PMC9867491
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Euro Surveill. 2021 Dec;26(49):
pubmed: 34886946
JAMA Intern Med. 2021 Feb 1;181(2):229-236
pubmed: 33165560
Euro Surveill. 2020 Jun;25(22):
pubmed: 32524949
Epidemics. 2022 Sep;40:100589
pubmed: 35691101
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Euro Surveill. 2021 Dec;26(48):
pubmed: 34857066
Lancet Healthy Longev. 2021 Mar;2(3):e129-e142
pubmed: 33655236
JMIR Public Health Surveill. 2020 May 26;6(2):e11512
pubmed: 32357126
Lancet Infect Dis. 2021 Apr;21(4):e67
pubmed: 32628906
Arch Public Health. 2022 Jan 29;80(1):45
pubmed: 35093169
Aging Dis. 2022 Apr 1;13(2):402-422
pubmed: 35371608
JAMA Intern Med. 2020 Aug 01;180(8):1101-1105
pubmed: 32437547
J Community Hosp Intern Med Perspect. 2021 Nov 15;11(6):733-739
pubmed: 34804382
Clin Microbiol Infect. 2022 Feb;28(2):279-284
pubmed: 34619398
Epidemiol Infect. 2022 Feb 22;150:e72
pubmed: 35403594
J Am Med Dir Assoc. 2021 Feb;22(2):256-257
pubmed: 33358724
J Am Geriatr Soc. 2020 Aug;68(8):1653-1656
pubmed: 32484912
Vaccine. 2022 Oct 12;40(43):6218-6224
pubmed: 36127210
Clin Infect Dis. 2021 Sep 15;73(6):e1365-e1367
pubmed: 33768222
Cell Rep Med. 2022 Mar 11;3(4):100583
pubmed: 35480627
Lancet Healthy Longev. 2020 Oct;1(1):e21-e31
pubmed: 34173614
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S163-S169
pubmed: 33119065
JAMA Intern Med. 2022 Jul 1;182(7):701-709
pubmed: 35486394
Viruses. 2022 Jun 22;14(7):
pubmed: 35891341

Auteurs

Sara Dequeker (S)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Milena Callies (M)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Lucy Catteau (L)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Laura Int Panis (L)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Esma Islamaj (E)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Sofieke Klamer (S)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Katrien Latour (K)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Marijke Pauwels (M)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Catharina Vernemmen (C)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Romain Mahieu (R)

Department of Infectious Disease Prevention and Control, Common Community Commission, Brussels-Capital Region, 1040 Brussels, Belgium.

Hanna Masson (H)

Agency for Care and Health, Infection Prevention and Control, Government of Flanders, 1000 Brussels, Belgium.

Muhammet Savsin (M)

Direction de la Recherche, de la Statistique et de la Veille des Politiques, AVIQ, 6061 Charleroi, Belgium.

Etienne De Clercq (E)

Iriscare, Brussels Public Agency for Health and Social Care, 1040 Brussels, Belgium.

Mireille Thomas (M)

Cellule des Maladies Infectieuses, Département Santé et Personnes Âgées, Ministère de la Communauté Germanophone, 4700 Eupen, Belgium.

Boudewijn Catry (B)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.
Faculty of Medecine, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium.

Eline Vandael (E)

Department of Epidemiology and Public Health, Sciensano, 1050 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH